Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02516332 · ClinicalTrials.gov registry record · NA

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

A NA study of Anxiety and Cardiovascular Disease, sponsored by Duke University.

Completed
Registry status
NA
Development phase
128
Enrollment target
1
Study location

NCT02516332 is a NA study of Anxiety and Cardiovascular Disease that has completed, run by Duke University. The registered enrollment target is 128 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02516332, a NA study of Anxiety and Cardiovascular Disease, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
128 participants
Enrollment target
1
Study location

Study Summary

Coronary heart disease (CHD) is the leading cause of death in the United States; more than 600,000 Americans suffer a fatal cardiac event each year. Traditional CHD risk factors such as high blood pressure, smoking, and elevated cholesterol do not fully account for the timing and occurrence of CHD events and individuals with elevated levels of anxiety appear to have a greater risk of cardiovascular events. The present study will examine the impact of aerobic exercise and Lexapro in the treatment of anxiety and cardiovascular biomarkers among individuals with CHD.

Interventions

  • DRUG Placebo
  • DRUG Lexapro
  • BEHAVIORAL Supervised Aerobic Exercise

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2015-12
Est. Completion 2021-05
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT02516332

The ClinicalTrials.gov registry entry for NCT02516332 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (71% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02516332 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02516332 about?

NCT02516332 is a clinical study titled "Exercise and Pharmacotherapy for Anxiety in Cardiac Patients". Coronary heart disease (CHD) is the leading cause of death in the United States; more than 600,000 Americans suffer a fatal cardiac event each year. Traditional CHD risk factors such as high blood pressure, smoking, and elevated cholesterol do not fully account for the timing and occurrence of CHD e...

What is the current status of trial NCT02516332?

This trial is currently completed. It is a NA study. The enrollment target is 128 participants. The study started on 2015-12. Estimated completion is 2021-05.

What conditions does trial NCT02516332 study?

This clinical trial studies the following conditions: Anxiety, Cardiovascular Disease.

What interventions are being tested in trial NCT02516332?

The interventions under investigation include: Placebo (DRUG), Lexapro (DRUG), Supervised Aerobic Exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT02516332?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02516332 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.